PROCEPT BIOROBOTICS CORP

PROCEPT insider sales reveal routine tax‑cover moves, not distress—executives’ growing stakes signal confidence in autonomous surgical tech.

Rohit Antal Rohit’s aggressive 2026 insider buying shows strong confidence in PROCEPT BioreRobotics’ autonomous tissue‑removal tech, hinting at a potential upside after a 50% drop.

Procept Biorobotics insider trades reveal cautious optimism—CTO Templin holds modest stake, execs buy/sell large shares amid AI‑powered pipeline and WATER IV trial.

Insider activity at Procept Biorobotics signals mixed confidence—CEO buying, exec sales—yet steady holdings suggest long‑term potential for autonomous tissue removal. Invest wisely.

PROCEPT insider sale under a 10b‑5‑1 plan shows routine liquidity moves, not a sign of distress, helping investors gauge short‑term price impact.

Alaleh’s disciplined 10b5‑1 sales reveal insider confidence amid a weak market, yet trigger caution for investors facing a 55% stock decline.

Kevin Waters’ recent PROCEPT BioRobotics share sale is a routine RSU tax‑planning move, not a warning sign – insiders remain firmly invested.

Alaleh’s modest 3,098‑share sale at $25.60 shows disciplined insider trading amid PROCEPT’s stock slide—investors can gauge future volatility from top‑executive moves.

PROCEPT BioRobotics insider buying signals confidence amid volatility—Alaleh’s recent PSU‑triggered purchase may hint at a future rebound for the struggling stock.